cellular therapies
gilead sciences pty ltd - axicabtagene ciloleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: albumin; sodium chloride; dimethyl sulfoxide - cellular therapies - yescarta is a genetically modified autologous immunocellular therapy for the treatment of relapsed or refractory large b-cell lymphoma after two or more lines of systemic therapy, including diffuse large b-cell lymphoma (dlbcl) not otherwise specified, primary mediastinal large b-cell lymphoma, high grade b-cell lymphoma, and dlbcl arising from follicular lymphoma. yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
actemra 20 mg/ml concentrado para solución para infusión i.v.
f. hoffmann la roche s.a. - tocilizumab - tocilizumab....20 mg
cellular therapies
gilead sciences pty ltd - brexucabtagene autoleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: albumin; dimethyl sulfoxide; sodium chloride - cellular therapies - tecartus is a genetically modified autologous immunocellular therapy for the treatment of patients with relapsed or refractory mantle cell lymphoma (mcl), who have received two or more lines of therapy, including a btk inhibitor, unless ineligible or intolerant to treatment with a btk inhibitor.
cellular therapies
gilead sciences pty ltd - axicabtagene ciloleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: dimethyl sulfoxide; sodium chloride; albumin - cellular therapies - yescarta is a genetically modified autologous immunocellular therapy for the treatment of:large b-cell lymphoma - patients with relapsed or refractory large b-cell lymphoma (lbcl).yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. follicular lymphoma - patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
actemra 20 mgml concentrate for solution for infusion.
roche (malaysia) sdn. bhd. - tocilizumab -
actemra 162mg solution for injection in pre-filled syringe 162mg0.9ml
roche singapore pte. ltd. - tocilizumab - injection, solution - tocilizumab 162 mg/0.9 ml
actemra
roche products pty ltd - tocilizumab -
actemra 80
roche products (pty) ltd - tocilizumab - solution for infusion - each 4 ml vial contains tocilizumab 80 mg
actemra concentrate solution for infusion 80 mg/4ml/vial
al jishi pharmacy - tocilizumab - concentrate solution for infusion - 80
actemra concentrate solution for infusion 200 mg/10ml/vial
al jishi pharmacy - tocilizumab - concentrate solution for infusion - 200